Inloggad som:

KarMMA-3

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

KarMMA-3
A PHASE 3, MULTICENTER, RANDOMIZED, OPENLABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF BB2121 VERSUS STANDARD TRIPLET REGIMENS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
A PHASE 3, MULTICENTER, RANDOMIZED, OPENLABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF BB2121 VERSUS STANDARD TRIPLET REGIMENS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 3
Palliativ
Företag

Studien ändrades senast av: studyjohanna (2020-08-25)

Tillbaka till listan